Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 3/20 | 0.51 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.51 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
| ▸ | MGAM | O43451 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | SI | P14410 | 2/20 | 0.51 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 3/20 | 0.48 |
| ▸ | GSK3A | P49840 | 2/20 | 0.48 |
| ▸ | CDC7 | O00311 | 1/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.48 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2880230 | 1.00 | MEN1 (0.55) | MEN1KMT2ANOD2PIM1PIM2 | |
| SCHEMBL2877653 | 0.81 | CISD1 (0.56) | PIM1PIM2PIM3PDE4BIGF1R | |
| SCHEMBL2877652 | 0.81 | CISD1 (0.56) | PIM1PIM2PIM3PDE4BIGF1R | |
| SCHEMBL12975487 | 0.81 | CISD1 (0.56) | PIM1PIM2PIM3PDE4BIGF1R | |
| SCHEMBL2883618 | 0.80 | PDE4B (0.58) | MEN1KMT2APIM1PIM2PIM3 | |
| SCHEMBL2883617 | 0.80 | PDE4B (0.58) | MEN1KMT2APIM1PIM2PIM3 | |
| SCHEMBL2885072 | 0.80 | AKR1B1 (0.50) | MEN1KMT2ANOD2MGAMGAA | |
| SCHEMBL2885069 | 0.80 | AKR1B1 (0.50) | MEN1KMT2ANOD2MGAMGAA | |
| SCHEMBL2881408 | 0.80 | FLT3 (0.43) | GAAHPGD | |
| SCHEMBL2883164 | 0.79 | CISD1 (0.54) | PIM1PIM2PIM3PDE4BIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | claimed |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | MERCK SERONO SA (CH) | 2009-02-12 | — | — | US | claimed |
| EP-1807075-A2 | PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA | Applied Research Systems ARS Holding N.V. (AN) | 2007-07-18 | — | — | EP | claimed |
| WO-2006040318-A2 | PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-04-20 | — | — | WO | claimed |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) | 2005-10-06 | — | — | US | claimed |
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | disclosed |
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | LABORATOIRES SERONO S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2008-12-11 | — | — | US | disclosed |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2006-06-08 | — | — | US | disclosed |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | ZAP70, BRCA1, ZYX | MEN1 1495/4885KMT2A 3006/4885NOD2 977/4885 |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | PDPK1, PRKD3, PRKD1 | MEN1 2366/4885KMT2A 1230/4885NOD2 4764/4885 |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | CATSPER1, PI4KB, MAN2B2 | MEN1 3768/4885KMT2A 2969/4885NOD2 4872/4885 |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | PDPK1, PIK3R4, MAP3K3 | MEN1 1758/4885KMT2A 603/4885NOD2 3636/4885 |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | BRCA1, ZAP70, F13B | MEN1 1543/4885KMT2A 3104/4885NOD2 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.